Literature DB >> 15135703

Usefulness of myocardial viability or ischemia in predicting long-term survival for patients with severe left ventricular dysfunction undergoing revascularization.

Lawrence Liao1, Christopher H Cabell, James G Jollis, Eric J Velazquez, William T Smith, Kevin J Anstrom, Paul A Pappas, Thomas Ryan, Joseph A Kisslo, Carolyn K Landolfo.   

Abstract

In 107 patients with coronary disease and severe left ventricular dysfunction, we examined the prognostic power of viability identified by dobutamine stress echocardiography. At a mean follow-up of 27 months, patients with viable myocardium who underwent revascularization had a significant survival advantage over all other patients (2-year survival 83.5% vs 57.2%, p = 0.0037).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15135703     DOI: 10.1016/j.amjcard.2004.01.071

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: A meta-analysis.

Authors:  Yoichi Inaba; Jennifer A Chen; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2010-04-09       Impact factor: 5.952

2.  Myocardial viability and survival in ischemic left ventricular dysfunction.

Authors:  Robert O Bonow; Gerald Maurer; Kerry L Lee; Thomas A Holly; Philip F Binkley; Patrice Desvigne-Nickens; Jaroslaw Drozdz; Pedro S Farsky; Arthur M Feldman; Torsten Doenst; Robert E Michler; Daniel S Berman; Jose C Nicolau; Patricia A Pellikka; Krzysztof Wrobel; Nasri Alotti; Federico M Asch; Liliana E Favaloro; Lilin She; Eric J Velazquez; Robert H Jones; Julio A Panza
Journal:  N Engl J Med       Date:  2011-04-04       Impact factor: 91.245

3.  Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial.

Authors:  Eileen O'Meara; Lisa M Mielniczuk; George A Wells; Robert A deKemp; Ran Klein; Doug Coyle; Brian Mc Ardle; Ian Paterson; James A White; Malcolm Arnold; Matthias G Friedrich; Eric Larose; Alexander Dick; Benjamin Chow; Carole Dennie; Haissam Haddad; Terrence Ruddy; Heikki Ukkonen; Gerald Wisenberg; Bernard Cantin; Philippe Pibarot; Michael Freeman; Eric Turcotte; Kim Connelly; James Clarke; Kathryn Williams; Normand Racine; Linda Garrard; Jean-Claude Tardif; Jean DaSilva; Juhani Knuuti; Rob Beanlands
Journal:  Trials       Date:  2013-07-16       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.